1. Home
  2. RVT vs MLYS Comparison

RVT vs MLYS Comparison

Compare RVT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Value Trust Inc.

RVT

Royce Value Trust Inc.

HOLD

Current Price

$16.41

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.59

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVT
MLYS
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RVT
MLYS
Price
$16.41
$23.59
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$48.67
AVG Volume (30 Days)
224.3K
1.1M
Earning Date
01-01-0001
03-12-2026
Dividend Yield
7.32%
N/A
EPS Growth
N/A
37.43
EPS
2.95
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.12
$10.44
52 Week High
$18.73
$47.65

Technical Indicators

Market Signals
Indicator
RVT
MLYS
Relative Strength Index (RSI) 39.18 37.39
Support Level $15.77 $12.98
Resistance Level $16.50 $31.09
Average True Range (ATR) 0.45 1.60
MACD -0.05 -0.08
Stochastic Oscillator 25.00 16.78

Price Performance

Historical Comparison
RVT
MLYS

About RVT Royce Value Trust Inc.

Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: